Modality
mRNA
MOA
GLP-1ag
Target
CGRP
Pathway
Checkpoint
RA
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
May 2018
→ May 2030
Phase 2Current
NCT04131758
2,890 pts·RA
2023-01→2030-05·Terminated
NCT03096957
591 pts·RA
2018-05→2028-07·Recruiting
3,481 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-07-232.3y awayPh2 Data· RA
2030-05-274.2y awayPh2 Data· RA
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Recruit…
P2
Termina…
Catalysts
Ph2 Data
2028-07-23 · 2.3y away
RA
Ph2 Data
2030-05-27 · 4.2y away
RA
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04131758 | Phase 2 | RA | Terminated | 2890 | SRI-4 |
| NCT03096957 | Phase 2 | RA | Recruiting | 591 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP |